Harleysville, Pennsylvania, USA, 15th of October 2013. Colorcon Inc. and Evonik Industries AG have announced the signing of a cooperation agreement for the marketing and technical support of Acryl-EZE®, aqueous acrylic enteric system.
Acryl-EZE® fully formulated coating systems are produced by Colorcon and contain EUDRAGIT® L 100-55, an Evonik product, as the key functional ingredient.
Prior to this new cooperation agreement, Acryl-EZE® was produced, distributed, marketed and supported solely by Colorcon. The new cooperation will result in enhanced global technical support to the pharmaceutical industry through the Evonik network as well as the established Colorcon channels.
Furthermore the cooperation will create value for customers who require high performance enteric acrylic coating solutions.
“Expanding our sales and marketing activities will enable us to reach and support more customers and offer them a broader technical service together with Evonik, a leading company in delayed release polymers. We are excited to enter this new cooperation” affirms Colorcon’s CEO Martti Hedman.
“Colorcon is a market leader in fully formulated film coating systems and Acryl-EZE® is well established in the pharmaceutical market. This new cooperation will expand our offering and bring more choices to the customers ranging from single functional excipients to fully formulated delayed release coating systems” comments Jean-Luc Herbeaux, Head of the Health Care Business Line, of Evonik Industries.
Company information
Colorcon is a world leader in the development, supply and support of formulated products for the pharmaceutical and nutritional industries. Its core businesses include film coatings, modified release technologies, functional excipients and tablet design services. Colorcon has 20 technical service laboratories globally and more than 1200 employees exclusively dedicated to its customer base. For more information, visit www.colorcon.com.
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.6 billion and an operating profit (adjusted EBITDA) of about €2.6 billion.
Help employers find you! Check out all the jobs and post your resume.
